Literature DB >> 31161076

Neurodevelopmental outcome in hypoplastic left heart syndrome after hybrid procedure.

Bettina Reich1, Kristina N Heye2, Kristina Wetterling3, Thushiha Logeswaran1, Andreas Hahn4, Hakan Akintürk1, Christian Jux1, Dietmar Schranz5.   

Abstract

BACKGROUND: Little is known about the mid-term outcome and brain development in patients following the hybrid approach for hypoplastic left heart syndrome (HLHS). This study investigates neurodevelopmental outcome, quality of life (QoL) and brain MRI findings in HLHS preschoolers treated with the hybrid approach.
METHODS: Twenty HLHS patients (60% males) have been examined after neonatal hybrid Stage I and comprehensive stage II operation at the Pediatric Heart Center Giessen, Germany, between 2012 and 2016. Patients were evaluated with the Bayley Scales of Infant and Toddler Development III (Bayley-III), neurological examination, the Preschool Children Quality of Life Questionnaire (TAPQOL) at age 26.5±3.6 months, and again at 39.7±3.9 months with the Pediatric Cardiac Quality of Life Inventory (PCQLI). Furthermore, brain volumetric measurements and conventional brain MRI findings (27.3±4.5 months) were analyzed and compared with six healthy controls (29.2±11.1 months, P=0.53). Children with verified genetic comorbidities were excluded.
RESULTS: Mean cognitive, language, and motor composite scores on the Bayley-III were not different from healthy norms (100±15), and were 101±9.3 (P=0.48), 100±13 (P=0.93), and 98±11.7 (P=0.45), respectively. Status post stroke was the most common brain MRI abnormality, and was found in 3/19 (16%) patients, most common affecting the middle cerebral artery territory. In comparison to controls, total white matter volumes were reduced (P=0.014), and cerebrospinal fluid (CSF) volumes were increased (P=0.042) in patients. Overall health-related QoL in 2 to 3 years aged children HLHS was good, but inferior scores in the motor subscale were noted compared to healthy norms (P=0.007). However, at 3 to 4 years, parents reported comparable QoL for their children in the PCQLI to children with biventricular heart lesion.
CONCLUSIONS: HLHS patients followed by hybrid approach without major complications show a favorable neurodevelopment at 2-3 years of age. Despite extensive health-related burden, the vast majority of Fontan preschoolers with HLHS showed a good health-related QoL. Nevertheless, comprehensive care and establishing routine follow-up examinations are important to recognize long-term challenges and further improve neurodevelopmental outcome of this high-risk patient population.

Entities:  

Keywords:  Congenital heart disease (CHD); brain development; hybrid procedure; hypoplastic left heart syndrome (HLHS); neurodevelopmental outcome

Year:  2019        PMID: 31161076      PMCID: PMC6514277          DOI: 10.21037/tp.2019.04.05

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


  43 in total

1.  Early prediction of neurologic outcome after perinatal depression.

Authors:  B L Hajnal; F Sahebkar-Moghaddam; A J Barnwell; A J Barkovich; D M Ferriero
Journal:  Pediatr Neurol       Date:  1999-11       Impact factor: 3.372

Review 2.  Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.

Authors:  Joseph J Volpe
Journal:  Lancet Neurol       Date:  2009-01       Impact factor: 44.182

3.  The paradigm shift toward surgical intervention for neonates with hypoplastic left heart syndrome.

Authors:  Gil Wernovsky
Journal:  Arch Pediatr Adolesc Med       Date:  2008-09

4.  The disability paradox: high quality of life against all odds.

Authors:  G L Albrecht; P J Devlieger
Journal:  Soc Sci Med       Date:  1999-04       Impact factor: 4.634

5.  Psychological and cognitive functioning in children and adolescents with congenital heart disease: a meta-analysis.

Authors:  Petra A Karsdorp; Walter Everaerd; Merel Kindt; Barbara J M Mulder
Journal:  J Pediatr Psychol       Date:  2006-12-20

Review 6.  Neurocognitive consequences of surgically corrected congenital heart defects: A review.

Authors:  M Miatton; D De Wolf; K François; E Thiery; G Vingerhoets
Journal:  Neuropsychol Rev       Date:  2006-09-08       Impact factor: 7.444

7.  Behavioral and cognitive status in school-aged children with a history of failure to thrive during early childhood.

Authors:  R A Dykman; P H Casey; P T Ackerman; W B McPherson
Journal:  Clin Pediatr (Phila)       Date:  2001-02       Impact factor: 1.168

8.  Aortic morphometry and microcephaly in hypoplastic left heart syndrome.

Authors:  Amanda J Shillingford; Richard F Ittenbach; Bradley S Marino; Jack Rychik; Robert R Clancy; Thomas L Spray; J William Gaynor; Gil Wernovsky
Journal:  Cardiol Young       Date:  2007-03-05       Impact factor: 1.093

9.  Early intervention and recovery among children with failure to thrive: follow-up at age 8.

Authors:  Maureen M Black; Howard Dubowitz; Ambika Krishnakumar; Raymond H Starr
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124

10.  Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children.

Authors:  M Fekkes; N C Theunissen; E Brugman; S Veen; E G Verrips; H M Koopman; T Vogels; J M Wit; S P Verloove-Vanhorick
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

View more
  3 in total

Review 1.  Recent advances in our understanding of neurodevelopmental outcomes in congenital heart disease.

Authors:  Brian R White; Lindsay S Rogers; Matthew P Kirschen
Journal:  Curr Opin Pediatr       Date:  2019-12       Impact factor: 2.856

Review 2.  MRI studies of brain size and growth in individuals with congenital heart disease.

Authors:  Alexandra F Bonthrone; Christopher J Kelly; Isabel H X Ng; Serena J Counsell
Journal:  Transl Pediatr       Date:  2021-08

Review 3.  Neuroplacentology in congenital heart disease: placental connections to neurodevelopmental outcomes.

Authors:  Rachel L Leon; Imran N Mir; Christina L Herrera; Kavita Sharma; Catherine Y Spong; Diane M Twickler; Lina F Chalak
Journal:  Pediatr Res       Date:  2021-04-16       Impact factor: 3.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.